Delcath Systems, Inc. (DCTH) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Unaudited Condensed Consolidated Financial Statements for the quarterly period ended March 31, 2026. Delcath Systems, Inc. is an interventional oncology company focused on treating cancers primary or metastatic to the liver. Its lead product, the HEPZATO KIT, is FDA-approved for uveal melanoma with hepatic metastases. The company also markets the CHEMOSAT hepatic delivery system in Europe.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $24.99 million | $19.78 million |
| Gross Profit | $21.26 million | $16.94 million |
| Gross Margin | 85.1% | 85.6% |
| Operating Loss | ($1.64 million) | $0.64 million (Income) |
| Net Loss | ($1.07 million) | $1.07 million (Income) |
| Cash & Cash Equivalents | $41.31 million | $12.78 million |
| Short-term Investments | $47.99 million | $46.10 million |
| Total Current Assets | $120.27 million | $119.53 million |
| Total Current Liabilities | $10.70 million | $10.95 million |
| Operating Cash Flow | $0.86 million | $2.20 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 26.3% year-over-year, driven primarily by a 29.0% increase in HEPZATO KIT sales ($23.25M vs. $18.02M). CHEMOSAT revenue remained flat at approximately $1.75M.
- Profitability Shift: The company reported a net loss of $1.07 million compared to net income of $1.07 million in Q1 2025. This reversal was caused by a significant increase in operating expenses.
- Expense Increases:
- R&D Expenses: Rose 96.2% to $9.82 million due to expanded clinical teams and Phase 2 trials for colorectal and breast cancer.
- SG&A Expenses: Increased 15.8% to $13.07 million due to commercial expansion and marketing activities.
- Liquidity Position: Cash and cash equivalents increased significantly to $41.3 million, bolstered by a strong investment portfolio ($48.0 million). The company maintains a current ratio of approximately 11.3x.
- Share Repurchases: The company repurchased 316,023 shares for $3.0 million during the quarter under a $25 million authorization program. Approximately $16.0 million remains available.
Guidance, Outlook, and Risks
- Clinical Pipeline:
- CHOPIN Trial: Announced positive Phase 2 results showing improved progression-free survival and overall survival when combining CHEMOSAT with immune checkpoint inhibitors.
- Phase 2 Trials: Enrollment began in Q3 2025 for liver-dominant metastatic colorectal cancer (mCRC). Enrollment for liver-dominant metastatic breast cancer (mBC) is expected to begin in Q2 2026.
- Liquidity Outlook: Management believes current cash, equivalents, and investments are sufficient to fund operations for at least 12 months.
- Regulatory & Commercial: The company is subject to the National Drug Rebate Agreement (NDRA) and Pharmaceutical Pricing Agreement (PPA) with CMS, requiring mandated rebates for Medicaid usage. No accrued rebates were recorded as of March 31, 2026.
- Risks: Key risks include the uncertainty of clinical trial outcomes, regulatory approvals for new indications, reimbursement challenges, and supply chain disruptions. The company also faces a contingent liability of approximately $0.84 million related to a settled dispute with medac GmbH.
Investor Verification Checklist
- Cash Burn vs. Revenue: Verify the sustainability of the current cash burn rate given the doubling of R&D expenses and the shift from net income to net loss.
- Customer Concentration: Review the concentration risk where two customers accounted for 26.5% of Q1 2026 revenue.
- Rebate Accruals: Monitor future quarters for the impact of the NDRA and PPA on net revenue as actual claims are processed.
- Clinical Milestones: Track enrollment progress and data readouts for the mCRC and mBC Phase 2 trials, which are critical for future revenue expansion.
- Share Repurchase Impact: Assess the impact of the $3.0 million share buyback on the company's liquidity runway.